All treatments
Treatment
Tarlatamab, Tarlatamab clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer
This study is looking at a new treatment called Tarlatamab for people with small cell lung cancer that has spread to the brain. It aims to see how well the treatment shrinks brain tumours and controls the cancer without causing symptoms.
For: patients with asymptomatic active brain metastases from small cell lung cancerNetherlands - AuthorisedTherapeutic exploratory (Phase II)
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
This study is testing a new medicine called tarlatamab for people with advanced small cell lung cancer that has already been treated. We want to see how well it helps people live longer and if it has any side effects, particularly for those who are a bit frailer.
For: Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2France · Greece · Spain